Novo Nordisk has written to suppliers seeking discounts to lower its cost base as it tries to regain leadership in the weight-loss drug market. The company confirmed the move, stating it aims to ensure partnerships remain commercially sustainable and that a positive response will be considered in broader supplier assessments, though participation is not mandatory. Danish business publication Finans first reported the news, noting some suppliers viewed the communication as a warning regarding future dealings. Eli Lilly currently leads the GLP-1 market with a 60% share, while Novo holds 40% as of the first quarter of 2026. The cost-cutting drive follows Novo's September announcement of plans to eliminate approximately 9,000 jobs globally under new CEO Mike Doustdar.
Novo Nordisk A/SNovo Nordisk seeks supplier discounts to cut costs, following 9,000 job cuts, indicating financial pressure.
Eli Lilly and CompanyNovo Nordisk's cost-cutting and market share loss to Eli Lilly (60% vs 40%) strengthens Lilly's competitive position.